Kaleido Total Debt Trend from 2010 to 2021

KLDO -  USA Stock  

USD 5.72  0.08  1.42%

Kaleido Biosciences Total Debt yearly trend continues to be quite stable with very little volatility. Total Debt may rise above about 21.3 M this year. From the period between 2010 and 2021, Kaleido Biosciences, Total Debt regression line of its data series had standard deviation of 2,766,858 and standard deviation of  2,766,858. Research and Development Expense is expected to rise to about 56 M this year, although the value of Consolidated Income will most likely fall to (88.1 M).

Search Historical Trends 

 
Refresh
Check Kaleido Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Kaleido main balance sheet or income statement drivers, such as Gross Profit of 872.4 K, Interest Expense of 2.2 M or Operating Expenses of 78.8 M, as well as many exotic indicators such as Asset Turnover of 0.0125, Book Value per Share of 0.66 or Current Ratio of 4.08. Kaleido financial statements analysis is a perfect complement when working with Kaleido Biosciences Valuation or Volatility modules. It can also supplement various Kaleido Biosciences Technical models. Please see the analysis of Kaleido Biosciences Correlation against competitors.

Kaleido Biosciences Quarterly Total Debt

21.34 MillionShare

Kaleido Total Debt Breakdown

Showing smoothed Total Debt of Kaleido Biosciences with missing and latest data points interpolated. Total Debt of Kaleido Biosciences is a combination of both Kaleido Biosciences short-term and long-term liabilities. Short-term debts are those that must be paid back within a year. This type of debt applies to things like lines of credit or short-term term bonds. Long-term debt of Kaleido Biosciences includes liability that must be paid off in more than a year. This typically includes large senior debts like mortgages, bonds, as well as business loans or leases. A component of Total Liabilities representing the total amount of current and non-current debt owed. Includes secured and unsecured bonds issued; commercial paper; notes payable; credit facilities; lines of credit; capital lease obligations; operating lease obligations; and convertible notes.Kaleido Biosciences' Total Debt historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Kaleido Biosciences' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 21.19 M10 Years Trend
Increasing
Slightly volatile
 Total Debt 
Share
      Timeline 

Kaleido Total Debt Regression Statistics

Arithmetic Mean 16,337,552
Geometric Mean 16,145,573
Coefficient Of Variation 16.94
Mean Deviation 2,287,827
Median 14,810,000
Standard Deviation 2,766,858
Range 6,529,618
R-Value 0.76
R-Squared 0.58
Significance 0.004127
Slope 583,178

Kaleido Total Debt History

201814.8 M
201920.4 M
202021 M
202121.3 M

Other Fundumenentals of Kaleido Biosciences

Kaleido Biosciences Total Debt component correlations

About Kaleido Biosciences Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Kaleido Biosciences income statement, its balance sheet, and the statement of cash flows. Kaleido Biosciences investors use historical funamental indicators, such as Kaleido Biosciences's Total Debt, to determine how well the company is positioned to perform in the future. Although Kaleido Biosciences investors may use each financial statement separately, they are all related. The changes in Kaleido Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Kaleido Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Kaleido Biosciences Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Kaleido Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2021
Total Debt21 M21.3 M
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts. Kaleido Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 82 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Kaleido Biosciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Global Markets Map Now

   

Global Markets Map

Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Kaleido Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see the analysis of Kaleido Biosciences Correlation against competitors. Note that the Kaleido Biosciences information on this page should be used as a complementary analysis to other Kaleido Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for Kaleido Stock analysis

When running Kaleido Biosciences price analysis, check to measure Kaleido Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kaleido Biosciences is operating at the current time. Most of Kaleido Biosciences' value examination focuses on studying past and present price action to predict the probability of Kaleido Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Kaleido Biosciences' price. Additionally, you may evaluate how the addition of Kaleido Biosciences to your portfolios can decrease your overall portfolio volatility.
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Commodity Channel Index
Use Commodity Channel Index to analyze current equity momentum
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
The market value of Kaleido Biosciences is measured differently than its book value, which is the value of Kaleido that is recorded on the company's balance sheet. Investors also form their own opinion of Kaleido Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Kaleido Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kaleido Biosciences' market value can be influenced by many factors that don't directly affect Kaleido Biosciences underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kaleido Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Kaleido Biosciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kaleido Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.